Recent Finacing
Recent Raise
Renalys Pharma is a Tokyo-based late-stage biopharmaceutical company developing sparsentan for IgA nephropathy in Asian patients, holding licensing rights and initiating an open-label Phase III following a PMDA IND.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
See the team members at Renalys Pharma.
